Aktienanalyse zu Nordicus Partners Corporation Common Stock (NORD)

KI-Analyse of Nordicus Partners Corporation Common Stock (NORD)

Kaufen

Nordstrom Inc (JWN) is a good buy right now due to its strong financial performance, highlighted by a gross margin of 39.04% and a significant increase in net income from $46 million in Q3 to $166 million in Q4. Additionally, hedge funds have increased their buying activity by 155.36% over the last quarter, indicating strong institutional interest. The main risk is the high debt-to-equity ratio of 229.65%, which could pose challenges if market conditions worsen.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Nordicus Partners Corporation Common Stock (NORD) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von .

Erwartetes KGV

5J-Durchschnitt P/E

Aktuelles P/E

0.00

Erwartetes EV/EBITDA

5J-Durchschnitt EV/EBITDA

Aktuelles EV/EBITDA

0.00

Erwartetes KUV

Fair bewertet

5J-Durchschnitt P/S

0.07

Aktuelles P/S

0.07

Überbewertet

0.08

Unterbewertet

0.06

NORD FAQ – beantwortet von Alphio AI

Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California. It operates in the Academic & Educational Services sector.

Nordstrom Inc (JWN) is a good buy right now due to its strong financial performance, highlighted by a gross margin of 39.04% and a significant increase in net income from $46 million in Q3 to $166 million in Q4. Additionally, hedge funds have increased their buying activity by 155.36% over the last quarter, indicating strong institutional interest. The main risk is the high debt-to-equity ratio of 229.65%, which could pose challenges if market conditions worsen.